• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

In vitro antibacterial activity of DR-3355, the S-(-)-isomer of ofloxacin.

作者信息

Fujimoto T, Mitsuhashi S

机构信息

Episome Institute, Gunma, Japan.

出版信息

Chemotherapy. 1990;36(4):268-76. doi: 10.1159/000238777.

DOI:10.1159/000238777
PMID:2174762
Abstract

DR-3355, the S-(-)-isomer of ofloxacin, possessed generally twice higher activity than ofloxacin, and its action was bactericidal. The difference in antibacterial activity of these compounds was attributable to their inhibitory activity against DNA gyrase. DR-3355 was characterized by its higher potency against gram-positive cocci and obligate anaerobes than ofloxacin and ciprofloxacin. DR-3355 was somewhat less potent than ciprofloxacin against Enterobacteriaceae and Pseudomonas aeruginosa, but was active against organisms resistant to cefteram, ceftazidime, and amikacin. The activity of DR-3355 was decreased by gyrA mutation, like that of the other quinolones, although it did not alter significantly by deficiency of outer membrane protein F or lipopolysaccharide. Moderately norfloxacin-resistant isolates of Staphylococcus aureus remained susceptible to DR-3355, but not to ciprofloxacin.

摘要

相似文献

1
In vitro antibacterial activity of DR-3355, the S-(-)-isomer of ofloxacin.
Chemotherapy. 1990;36(4):268-76. doi: 10.1159/000238777.
2
The comparative activity of fleroxacin, three other quinolones and eight unrelated antimicrobial agents.氟罗沙星、其他三种喹诺酮类药物及八种不相关抗菌药物的比较活性
Chemotherapy. 1992;38(5):308-18. doi: 10.1159/000239019.
3
Antibacterial activities of grepafloxacin, ciprofloxacin, ofloxacin and fleroxacin.格雷帕沙星、环丙沙星、氧氟沙星和氟罗沙星的抗菌活性。
J Chemother. 1997 Feb;9(1):9-16. doi: 10.1179/joc.1997.9.1.9.
4
Comparative in vitro activity of fleroxacin, two other quinolones and three board-spectrum beta-lactams using the E-Test.
Chemotherapy. 1994 Sep-Oct;40(5):293-8. doi: 10.1159/000239209.
5
In vitro activity of S-ofloxacin.司氟沙星的体外活性
Antimicrob Agents Chemother. 1989 Jul;33(7):1105-7. doi: 10.1128/AAC.33.7.1105.
6
North American (United States and Canada) comparative susceptibility of two fluoroquinolones: ofloxacin and ciprofloxacin. A 53-medical-center sample of spectra of activity. North American Ofloxacin Study Group.北美(美国和加拿大)两种氟喹诺酮类药物(氧氟沙星和环丙沙星)的敏感性比较。53个医学中心的活性谱样本。北美氧氟沙星研究组。
Diagn Microbiol Infect Dis. 1994 Jan;18(1):49-56. doi: 10.1016/0732-8893(94)90133-3.
7
Levofloxacin in vitro activity: results from an international comparative study with ofloxacin and ciprofloxacin.
J Chemother. 1994 Apr;6(2):83-91. doi: 10.1080/1120009x.1994.11741134.
8
In vitro activity of temafloxacin hydrochloride (TA-167 or A-62254), a new fluorinated 4-quinolone.新型氟化4-喹诺酮盐酸替马沙星(TA-167或A-62254)的体外活性
Chemotherapy. 1990;36(5):345-55. doi: 10.1159/000238787.
9
[In vitro and in vivo antibacterial activities of a new quinolone derivative, FD501].
Jpn J Antibiot. 1996 Mar;49(3):264-72.
10
In vitro activity of DR-3355, an optically active ofloxacin.光学活性氧氟沙星DR-3355的体外活性
Antimicrob Agents Chemother. 1988 Sep;32(9):1336-40. doi: 10.1128/AAC.32.9.1336.

引用本文的文献

1
Combined substituent number utilized machine learning for the development of antimicrobial agent.联合取代基编号利用机器学习来开发抗菌剂。
Sci Rep. 2024 Feb 19;14(1):4106. doi: 10.1038/s41598-024-53888-2.
2
Characterization and its potential application of two esterases derived from the arctic sediment metagenome.源自北极沉积物宏基因组的两种酯酶的表征及其潜在应用
Mar Biotechnol (NY). 2009 May-Jun;11(3):307-16. doi: 10.1007/s10126-008-9145-2. Epub 2008 Sep 24.
3
Penetration of topically applied levofloxacin 0.5% and ofloxacin 0.3% into the vitreous of the non-inflamed human eye.
局部应用的0.5%左氧氟沙星和0.3%氧氟沙星在非炎症人眼玻璃体中的渗透情况。
Graefes Arch Clin Exp Ophthalmol. 2006 Dec;244(12):1633-7. doi: 10.1007/s00417-006-0360-0.
4
Pharmacokinetics and pharmacodynamics of levofloxacin in intensive care patients.左氧氟沙星在重症监护患者中的药代动力学和药效学
Clin Pharmacokinet. 2005;44(6):627-35. doi: 10.2165/00003088-200544060-00004.
5
Levofloxacin pharmacokinetics and serum bactericidal activities against five enterobacterial species.左氧氟沙星对五种肠杆菌属细菌的药代动力学及血清杀菌活性
Antimicrob Agents Chemother. 2000 Dec;44(12):3478-80. doi: 10.1128/AAC.44.12.3478-3480.2000.
6
Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers.健康志愿者中多次口服每日一次750毫克和1克剂量左氧氟沙星的安全性和药代动力学的双盲评估。
Antimicrob Agents Chemother. 1998 Apr;42(4):885-8. doi: 10.1128/AAC.42.4.885.
7
Absorption of ofloxacin isomers in the rat small intestine.大鼠小肠中氧氟沙星异构体的吸收情况。 需注意,原文中“Absorption of ofloxacin isomers in the rat small intestine.”多了一个“of”,正确表述应该是“Absorption of ofloxacin isomers in the rat small intestine.”
Antimicrob Agents Chemother. 1997 Oct;41(10):2274-7. doi: 10.1128/AAC.41.10.2274.
8
Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses.每日一次口服或静脉注射500毫克左氧氟沙星后的药代动力学特征。
Antimicrob Agents Chemother. 1997 Oct;41(10):2256-60. doi: 10.1128/AAC.41.10.2256.
9
Effects of food and sucralfate on a single oral dose of 500 milligrams of levofloxacin in healthy subjects.食物和硫糖铝对健康受试者单次口服500毫克左氧氟沙星的影响。
Antimicrob Agents Chemother. 1997 Oct;41(10):2196-200. doi: 10.1128/AAC.41.10.2196.
10
A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia.一项多中心随机研究,比较静脉注射和/或口服左氧氟沙星与头孢曲松和/或头孢呋辛酯治疗成人社区获得性肺炎的疗效和安全性。
Antimicrob Agents Chemother. 1997 Sep;41(9):1965-72. doi: 10.1128/AAC.41.9.1965.